“The i31-SLNB Identifies Patients With Cutaneous Melanoma Who Have Less Than 5% Risk of SLN Positivity While the CP-GEP Does Not”. SKIN The Journal of Cutaneous Medicine 9, no. 2 (March 17, 2025): s563. Accessed April 17, 2026. https://skin.dermsquared.com/skin/article/view/3289.